Encyclopedia of Signaling Molecules

2018 Edition
| Editors: Sangdun Choi

Cardiac Troponin Complex: Cardiac Troponin C (TNNC1), Cardiac Troponin I (TNNI3), and Cardiac Troponin T (TNNT2)

Reference work entry
DOI: https://doi.org/10.1007/978-3-319-67199-4_101901


Historical Background

The modern molecular understanding of muscle contraction took shape in the 1950s and 1960s. The sliding filament model was proposed in 1954, and it was known that muscle contraction was driven by myosin ATPase in the presence of actin. In the early 1960s, it was suspected, though not widely accepted, that muscle contraction is triggered by calcium. The idea was controversial, because while native preparations of actomyosin could be induced to relax by calcium-chelating agents, highly purified and reconstituted actomyosin did not display this behavior. In 1963, Ebashi demonstrated that the calcium dependence of skeletal muscle actomyosin activation was conferred by a third protein component, termed “native tropomyosin” or “tropomyosin-like protein” (Ebashi 1963). It resembled tropomyosin but was larger than the tropomyosin protein described by Bailey in 1946. In 1965, Ebashi and Kodama discovered that “native tropomyosin” was composed of tropomyosin and another component they named “troponin” (Ebashi and Kodama 1965). In 1971, Greaser and Gergely demonstrated that troponin is in fact made up of three separate subunits: calcium-binding troponin C (TnC), inhibitory troponin I (TnI), and tropomyosin-binding troponin T (TnT) (Greaser and Gergely 1971).

Biological Context

The troponin complex controls the calcium-dependent contraction and relaxation of striated muscle, which is either skeletal or cardiac (as opposed to smooth muscle). The characteristic striated appearance of these muscle types derives from the tandem arrangement of sarcomeres, the basic repeating units of contraction. Each sarcomere is bounded by two Z-discs, which anchor actin-containing thin filaments from neighboring sarcomeres. At the center of each sarcomere lies a hexagonally arranged lattice of bipolar myosin thick filaments. As put forth in the sliding filament model, activation of myosin ATPase powers muscle contraction by pulling the actin thin filaments towards the center of the sarcomere. This causes the thin filaments to slide against thick filaments, increasing their degree of overlap and reducing the length of the sarcomere.

Thin filaments are organized into repeating structural units, 38.5 nm long, each containing 14 actin monomers arranged as a twisted “double string of beads.” Tropomyosin forms a parallel coiled coil homodimer, with each homodimer lying across seven helically arranged actin monomers on each side of the thin filament. Thus, there are two diametrically opposed tropomyosin homodimers in a single 38.5 nm unit, each associated with a troponin complex. Tropomyosin further polymerizes in a head-to-tail manner to cover the entire length of the thin filament, except at the Z-disc.

Striated muscle contraction is regulated in a calcium-dependent manner through the action of tropomyosin and the troponin complex. At low Ca2+ concentration, troponin maintains tropomyosin in a position that blocks the interaction between myosin and actin, shutting off muscle contraction. The release of Ca2+ from the sarcoplasmic reticulum increases the cytoplasmic concentration of Ca2+, and Ca2+ binding to troponin results in a conformational change within the troponin complex that releases tropomyosin into a position that allows for actin-myosin interaction and muscle contraction.

Troponin subunits are encoded by separate homologous genes for each muscle type: cardiac, slow skeletal (type 1), and fast skeletal (type 2) (Fig. 1). Both TnI and TnT have three muscle type-specific isoforms, whereas TnC is expressed in two isoforms. Cardiac and slow skeletal muscle share one isoform encoded by TNNC1, and fast skeletal muscle has its own isoform encoded by TNNC2 (Li and Hwang 2015). Both cardiac TnC (cTnC) and fast skeletal TnC (sTnC) isoforms are expressed in embryonic skeletal muscle during development. However, gene expression of cTnC is switched off during the transition to fast skeletal muscle.
Cardiac Troponin Complex: Cardiac Troponin C (TNNC1), Cardiac Troponin I (TNNI3), and Cardiac Troponin T (TNNT2), Fig. 1

Striated muscle-specific expression of troponin subunits

The three isoforms of TnI are slow skeletal ssTnI (TNNI1), fast skeletal fsTnI (TNNI2), and cardiac cTnI (TNNI3) (Sheng and Jin 2016). During fetal development, the slow skeletal isoform is expressed in the heart, but it is completely replaced by cardiac isoform shortly after birth. TNNI3 is the sole isoform for the heart throughout adult life, and this does not change through pathologic states such as heart failure.

There are three muscle type-specific isoforms of TnT present in vertebrates: slow skeletal ssTnT (TNNT1), cardiac cTnT (TNNT2), and fast skeletal fsTnT (TNNT3) (Wei and Jin 2016). Their expression is fiber specific, with TNNT1 and TNNT3 expressed in slow and fast skeletal muscle, respectively. TNNT2 is expressed in cardiac muscle, but it is also expressed in embryonic skeletal muscle.

The presence of tissue-specific isoforms is clinically important. The measurement of elevated cTnI and cTnT levels in the serum is a very specific marker for myocardial damage. Detection of cTnI or cTnT has thus become the gold standard for diagnosing non-ST elevation myocardial infarction (NSTEMI). More recently, the detection of cTnI and cTnT has become so sensitive that low levels can be detected even in healthy individuals, and chronically elevated levels indicate increased cardiovascular risk (de Lemos et al. 2010).

Mutations in the cardiac isoforms of troponin give rise to heritable cardiomyopathies, all of which are associated with a risk of arrhythmias and progression to heart failure (Lu et al. 2013). Hypertrophic cardiomyopathy is the most common, with an estimated prevalence of 1:500. Its most prominent feature is abnormal hypertrophy of the ventricles, particularly in the ventricular septum. This process can lead to left ventricular outflow tract obstruction. There is some overlap between mutations causing hypertrophic cardiomyopathy and restrictive cardiomyopathy, with restrictive cardiomyopathy being a rarer and severe condition characterized by impaired relaxation and filling of the ventricles, leading to right-sided heart failure. Dilated cardiomyopathy is associated with enlarged thin-walled ventricles, generally leading to left-sided heart failure. A better understanding of the structure and function of the cardiac troponin complex is needed to explain the pathogenesis of the cardiomyopathies. One complicating factor is that the evidence linking some mutations to cardiomyopathies is poor, with some mutations only having been observed in a single individual. Without more data, it is difficult to determine whether some mutations are truly disease-causing alterations or just incidental benign polymorphisms.

Cardiac Troponin C (cTnC)

Structure and Function of cTnC

Cardiac troponin C is the calcium-binding subunit of the cardiac troponin complex, belonging to the EF hand superfamily of calcium-binding proteins. Each Ca2+-binding loop consists of 12 amino acid residues and is rich in aspartate and glutamate residues. Six residues 1(X), 3(Y), 5(Z), 7(-X), 9(-Y), and 12(-Z) in the loop provide oxygen ligands to coordinate the Ca2+ ion. X-ray and NMR studies reveal that cTnC adopts a dumbbell-shaped structure with two globular domains connected by a flexible linker (Sia et al. 1997; Takeda et al. 2003). NMR relaxation studies show that the two domains of cTnC tumble independently and are able to adopt various domain orientations in the absence of the other troponin subunits (Gaponenko et al. 1999).

The C-terminal domain of troponin C is the structured hub of the troponin complex, at the center of the so-called I-T arm featured in the 2003 X-ray crystal structure (Takeda et al. 2003) (Fig. 2). It has two high-affinity Ca2+-binding sites (EF III and EF IV), which are continually occupied throughout the cardiac cycle. In contrast, the regulatory N-terminal domain (cNTnC) has only a single low-affinity Ca2+-binding site (EF II). The defunct EF I calcium-binding site is inactive because of a single residue Val28 insertion and two chelating residue D29L and D31A substitutions (Fig. 3). The lone functional EF hand II Ca2+-binding site in cNTnC dictates the calcium dependence of contraction and relaxation in the sarcomere. It is largely unoccupied during diastole, but becomes occupied as the cytoplasmic concentration of calcium increases during systole. Calcium binding leads to a conformational shift from the closed to open state by moving the helical B-C pair away from helical unit N, A, D. This exposes a large hydrophobic pocket in cNTnC. (Actually, there is a rapid equilibrium between closed and open states in which the closed state predominates (Sia et al. 1997)). The open form is stabilized by binding of the switch peptide of troponin I (cTnI 146–158) (Li et al. 1999), and this promotes the detachment of the adjacent cTnI inhibitory region (cTnI135–147) from its binding site on actin, releasing tropomyosin to a position that promotes muscle contraction through actin-myosin cross-bridging.
Cardiac Troponin Complex: Cardiac Troponin C (TNNC1), Cardiac Troponin I (TNNI3), and Cardiac Troponin T (TNNT2), Fig. 2

Cardiac troponin complex. Troponin C consists of two domains shown in blue (cNTnC [1–85]) and green (cCTnC [93–161]). Troponin I is shown in red (cTnI [1–88]) and (cTnI [89–209]). The C-terminal fragment of troponin T (cTnT [226–288]) is shown in gray. Intrinsically disordered regions of troponin I and T have been drawn in as arbitrary squiggles. Calcium ions are shown as yellow spheres. Figure prepared using PyMOL and structure 4Y99 (PDB code)

Cardiac Troponin Complex: Cardiac Troponin C (TNNC1), Cardiac Troponin I (TNNI3), and Cardiac Troponin T (TNNT2), Fig. 3

Amino acid sequence of cTnC and its nine helices. Calcium-coordinating EF-hand positions 1, 3, 5, 7, 9, and 12 are marked in green. EF-hand I in cTnC is inactive, denoted with an asterisk and nonchelating residue substitutions highlighted in red

Cardiomyopathy-Associated cTnC Mutations

So far, in cTnC, at least seven mutations linked with HCM (A8V, L29Q, A31S, C84Y, Q122AfsX30, E134D, D145E) and seven mutations associated with DCM have been reported (Y5H, Q50R, E59D/D75Y, M103I, D145E, I148V, G159D) (Fig. 4) (Li and Hwang 2015). As cTnC has two different conformations, one closed and the other open and bound to cTnI switch region, it would make sense that mutations destabilizing the two different states in the context of intact thin filament would give rise to HCM and DCM, respectively (and this might hold true for cTnI and cTnT as well). However, the exact mechanism by which mutations in the cardiac troponin complex give rise to cardiomyopathies is still being worked out.
Cardiac Troponin Complex: Cardiac Troponin C (TNNC1), Cardiac Troponin I (TNNI3), and Cardiac Troponin T (TNNT2), Fig. 4

The structural domains of cTnC and reported cardiomyopathy-associated mutations

Cardiac Troponin I (cTnI)

Structure and Function of cTnI

There is inconsistent numbering in the literature for the amino acid sequence of cTnI, because the N-terminal methionine is removed and replaced by an acetyl group in posttranslational processing. We will refer to the N-terminal alanine as Ala1 rather than Ala2. Unlike troponin C, which forms two globular domains, troponin I is an intrinsically disordered protein with no regular structure on its own, though it acquires predominantly helical structure as it interacts with its many binding partners (Takeda et al. 2003). Along its 209-amino acid sequence cTnI has binding sites for cTnC, cTnT, tropomyosin, and actin. There are at least five distinct regions (Fig. 5a):
  1. (a)

    The cardiac-specific N-terminal extension (cTnI 1–31 ) is absent in fast and slow skeletal muscle TnI. The region is intrinsically disordered and invisible in the crystal structure of the cardiac troponin complex (Takeda et al. 2003). cTnI19–37 interacts electrostatically with cNTnC, which allows this region to remain disordered even within the troponin complex (Hwang et al. 2014). This interaction fixes the domain orientation of cNTnC relative to the rest of the troponin complex, positioning it optimally to bind the cTnI switch region. By promoting the interaction between cNTnC and the cTnI switch region, the Ca2+-bound open conformation of cNTnC is favored, and the apparent calcium affinity of cNTnC is enhanced.

  2. (b)

    The IT arm region (cTnI39–136) forms two α helices, cTnI39–79 and cTnI88–136. cTnI39–60 binds tightly to the hydrophobic cleft of cCTnC. cTnI88–136 forms a coiled coil with cTnT225–276, while cTnT225–276 binds to the other side of cCTnC (see Fig. 2). The IT arm constitutes the main structured core of the troponin complex. It is not known to bind directly to actin or tropomyosin.

  3. (c)

    The inhibitory region (cTnI135–147) interacts with actin to anchor the tropomyosin-troponin complex in a blocked state that shuts down muscle contraction.

  4. (d)

    The switch region (cTnI146–158) binds to cNTnC in a Ca2+-dependent manner, relieving the inhibition of adjacent sequences and facilitating the initiation of cardiac muscle contraction in systole.

  5. (e)
    The C-terminal actin-tropomyosin-binding site (cTnI159–209) enhances the inhibitory effect of the inhibitory region (cTnI135–147) (Tripet et al. 1997). The region is intrinsically disordered, although it may acquire some structure upon binding to actin-tropomyosin.
    Cardiac Troponin Complex: Cardiac Troponin C (TNNC1), Cardiac Troponin I (TNNI3), and Cardiac Troponin T (TNNT2), Fig. 5

    (a) The structural and functional regions of cTnI with interacting binding region of cTnC, cTnT, and actin. (b) Cardiomyopathy-associated mutations and phosphorylation sites


Posttranslational Modifications of cTnI

Posttranslational modifications of cTnI play a major role in regulating cardiac troponin activity. cTnI contains 3 tyrosine, 12 serine, and 8 threonine residues, many of which have been identified as phosphorylation sites, including Ser4, Ser5, Ser22, Ser23, Tyr25, Ser41, Ser43, Thr50, Ser76, Thr77, Thr142, Ser165, Thr180, and Ser198 (Zhang et al. 2012) (Fig. 5b). The most consistently identified phosphorylation sites in humans are Ser22/Ser23, which are phosphorylated by cyclic AMP-dependent protein kinase A (PKA) during β-adrenergic signaling (Solaro et al. 2013). However, these two serine residues can also be phosphorylated by several other protein kinases in vitro: protein kinase C (PKC), protein kinase D (PKD), and GMP-dependent protein kinase (PKG). Phosphorylation at these sites weakens the interaction between cTnI19–37 and cNTnC, promoting cardiac muscle relaxation by decreasing the calcium affinity of cNTnC (Zhang et al. 1995). Ser22 and Ser23 are highly phosphorylated in healthy individuals, whereas the levels of phosphorylation become reduced in heart failure (both heart failure with reduced ejection fraction and heart failure with preserved ejection fraction), as well as in hypertrophic and dilated cardiomyopathy (Wijnker et al. 2014).

Cardiomyopathy-Associated cTnI Mutations

Approximately 95% of the disease-causing mutations in cTnI are located in its C-terminal region, spanning residues 135 to 209 (Lu et al. 2013) (Fig. 5b). Almost all of these are associated with hypertrophic or restrictive cardiomyopathy (with the exception of N184K). This is consistent with the main physiologic role of this region, binding to actin-tropomyosin to maintain the thin filament in an inactive state. When this function is disrupted by mutation, the result is a hyperactivated thin filament with an associated increase in calcium sensitivity. Several cTnI mutations (L143Q, R144W, A170T, K177E, D189G, and R191H) in restrictive cardiomyopathy (RCM) patients showed greater Ca2+-sensitizing effects in cardiac muscle force generation compared to HCM mutations (Gomes et al. 2005b). At low Ca2+ concentration, these mutations also increased the force generation of cardiac muscle in the resting state. Interestingly, many of the mutations associated with RCM and HCM involve positively charged residues, underscoring the importance of electrostatic interactions, a recurrent theme for the intrinsically disordered segments of troponin.

Some mutations have also been reported in the N-terminal cardiac-specific extension of cTnI. One of these, R20C, has been linked to HCM (Gomes et al. 2005a). The mutation disrupts the phosphorylation consensus sequence, RRXS, of protein kinase A, abolishing the phosphorylation of Ser22 and Ser23. An additional four mutations (A1V, K35Q, N184K, and P15T) have been identified that have been associated with DCM in an autosomal dominant manner (Lu et al. 2013).

Cardiac Troponin (cTnT)

Variable Lengths of cTnT via Alternative Splicing

Cardiac troponin T is comparatively longer than the slow and fast skeletal muscle isoforms because of a long N-terminal hypervariable region, whereas the middle and C-terminal regions are highly conserved in all isoforms across different species (Wei and Jin 2016). Exons 2 and 3 of all isoforms are nearly identical, but exons 4 to 8 are highly variable. Combinatorial alternative splicing of exons 4 and 5, located in the N-terminal variable region, generates four different cTnT isoforms: cTnT1 (298 amino acids) has both exons 4 and 5 present, whereas in cTnT4 (283 amino acids) they are spliced out. For cTnT2 (293 amino acids) and cTnT3 (288 amino acids), exon 4 or 5 is spliced out, respectively (Fig. 6). Exon 13, which contains just three amino acids, has also been found to be spliced out under some circumstances. Varying levels of cTnT isoforms are expressed in normal development and in pathologic states. In the embryonic heart, cTnT1 is the dominant isoform, with cTnT2 expressed to a lesser extent. During prenatal development, the expression level of cTnT1 decreases, while the expression of cTnT3 increases to eventually become the dominant isoform of cTnT in adult heart. The cTnT4 isoform of cTnT has been found not only in fetal heart but also in failing adult heart. Exon 5, which is expressed in embryonic heart but missing in adult heart, contains eight negatively charged amino acids. These additional acidic residues appear to contribute to a higher Ca2+ sensitivity of muscle contraction (Wei and Jin 2016).
Cardiac Troponin Complex: Cardiac Troponin C (TNNC1), Cardiac Troponin I (TNNI3), and Cardiac Troponin T (TNNT2), Fig. 6

Alternative splicing of cTnT to yield four cardiac-specific isoforms. Alternative splicing out of exons 4 and 5 is shown in black. Exon 13 can also be spliced out and is shown in black

Structure and Function of cTnT

Classically, troponin T is divided into two functionally distinct fragments through partial proteolytic cleavage by chymotrypsin. The first fragment, T1, contains the N-terminal acidic hypervariable region followed by a tropomyosin-binding site (Fig. 6). There is a corresponding X-ray crystal structure of a short cTnT-derived peptide bound to the head-to-tail junction of tropomyosin (Murakami et al. 2008), but beyond this, precise structural details of the interaction between cTnT and tropomyosin are lacking. The second troponin T fragment, T2, contains a second tropomyosin-binding site, followed by a C-terminal region, which interacts with cTnC and cTnI to form the I-T arm of the troponin complex. It is known that the second tropomyosin-binding site of cTnT binds near Cys190 of tropomyosin (Ishii and Lehrer 1991), indicating that cTnT forms an elongated structure between its two tropomyosin-binding sites. cTnT224–274 forms a coiled coil with cTnI89–135, with a small stretch, cTnT259–270, also binding to the C-terminal domain of cTnC (Takeda et al. 2003) (Fig. 2). This arrangement places the C-terminal tail of cTnT, cTnT275–288, spatially adjacent to the key cTnI135–147 inhibitory region that is essential for binding to actin and shutting off muscle contraction in diastole. The exact role of cTnT275–288 is unknown, but it is also important in promoting relaxation (Franklin et al. 2012).

Phosphorylation Modifications of cTnT

PKA is a key player for phosphorylation-dependent regulation of a number of myofilament proteins, but not for any isoforms of cTnT. Ser2 was the first phosphorylation site identified in the 1980s, highly conserved among all three isoforms. However, the responsible kinase, regulatory mechanisms, and functional and structural importance have yet to be determined. Several serine and threonine residues in the middle and C-terminal regions of cTnT are phosphorylated by PKC: Thr194, Ser198, Thr203, and Thr284 (numbering according to the 288-amino acid adult heart cTnT3) (Fig. 7). Phosphorylation of Thr203 by PKCα alone resulted in a significant decrease in maximum force generation, as well as a decrease in myofilament Ca2+ sensitivity and cooperativity (Sumandea et al. 2003). Thr203 has also been reported to be phosphorylated by Raf-1 kinase. Several phosphorylation sites from C -terminal conserved region were identified and phosphorylated by apoptosis signal-regulating kinase (ASK1) and Rho-dependent kinase 2 (ROCK2) (Wei and Jin 2016). ASK1 can be activated in intracellular signaling cascades by stress stimuli like TNFα and the presence of reactive oxygen species. ASK1-mediated phosphorylation at Thr194 and Ser198 resulted in reduced contractility in cardiomyocytes. ROCK2 phosphorylation of cTnT at Ser275 and Thr284 reduced Mg-ATPase activity and maximum myofilament tension.
Cardiac Troponin Complex: Cardiac Troponin C (TNNC1), Cardiac Troponin I (TNNI3), and Cardiac Troponin T (TNNT2), Fig. 7

Cardiomyopathy-associated mutations and phosphorylation sites found in cTnT (adult heart isoform cTnT3 numbering, 288 a.a)

Cardiomyopathy-Associated cTnT Mutations

Mutations in cTnT account for approximately 15% of familial HCM cases. Functional studies of HCM-associated mutations of cTnT (I79N, R92W, R92Q, R94L, A104V, R130C, ΔE160, and E244D, numbering from adult heart cTnT3) did not show significant perturbation in maximum force generation or maximum myosin ATPase activity, but showed increased Ca2+ sensitivity in skinned fibers (Lu et al. 2013). Most of the HCM-linked mutations of cTnT reside in the first tropomyosin-binding region and impair the inhibitory role of cTnI in the thin filament. Restrictive cardiomyopathy causing mutations (ΔE96 and E136K) showed significant and large increases in Ca2+ sensitivity in skinned fibers leading to severe diastolic dysfunction (Parvatiyar et al. 2010). A double deletion mutation (N100 and E101) found in a RCM pediatric patient also demonstrated a similar trend of increased Ca2+ sensitivity (Pinto et al. 2011) (Fig. 7). A deletion mutation ΔK210 was reported as a DCM-associated mutation in cTnT, which decreased the Ca2+ sensitivity in force development and also reduced the ATPase activity in cardiac myofibrils (Morimoto et al. 2002). To date, several DCM-linked mutations of cTnT have been reported (R131W, R141W, R205L, ΔK210, and D270N) (Lu et al. 2013). The R141W mutation of cTnT located in tropomyosin-binding site stabilizes the interaction of cTnT with tropomyosin, promoting cTnI-mediated inhibition of the thin filament and causing Ca2+ desensitization (Sommese et al. 2013).

Summary and Future Directions

The cardiac troponin complex plays a central role in turning cardiac contraction on and off with every heartbeat. While its central structural scaffold has been decisively determined by X-ray crystallography, the more disordered regions that interact with tropomyosin and actin need further characterization in order to fully understand the structure and function of the intact complex. Most of the splicing-induced and posttranslational modifications occur in these regions to modulate cardiac function. When these modifications occur in disease, it must be determined how they interact with cardiomyopathy-associated mutations and whether they are pathologic disease-promoting changes or useful physiologic adaptations. Small molecule pharmacotherapy can be used to modulate the functioning of the cardiac troponin complex, either directly through the globular regulatory cNTnC domain or indirectly through signaling pathways. Such treatments can be anticipated to be useful not only in the treatment of heritable cardiomyopathies, but also in a wide range of other cardiac diseases in which heart function is compromised.


  1. de Lemos JA, Drazner MH, Omland T, Ayers CR, Khera A, Rohatgi A, et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA. 2010;304:2503–12. doi: 10.1001/jama.2010.1768.CrossRefPubMedPubMedCentralGoogle Scholar
  2. Ebashi S. Third component participating in the superprecipitation of ‘Natural Actomyosin’. Nature. 1963;200:1010.CrossRefPubMedGoogle Scholar
  3. Ebashi S, Kodama A. A new protein factor promoting aggregation of tropomyosin. J Biochem. 1965;58:107–8.CrossRefPubMedGoogle Scholar
  4. Franklin AJ, Baxley T, Kobayashi T, Chalovich JM. The C-terminus of troponin T is essential for maintaining the inactive state of regulated actin. Biophys J. 2012;102:2536–44. doi: 10.1016/j.bpj.2012.04.037.CrossRefPubMedPubMedCentralGoogle Scholar
  5. Gaponenko V, Abusamhadneh E, Abbott MB, Finley N, Gasmi-Seabrook G, Solaro RJ, et al. Effects of troponin I phosphorylation on conformational exchange in the regulatory domain of cardiac troponin C. J Biol Chem. 1999;274:16681–4.CrossRefPubMedGoogle Scholar
  6. Gomes AV, Harada K, Potter JD. A mutation in the N-terminus of troponin I that is associated with hypertrophic cardiomyopathy affects the Ca(2+)-sensitivity, phosphorylation kinetics and proteolytic susceptibility of troponin. J Mol Cell Cardiol. 2005a;39:754–65. doi: 10.1016/j.yjmcc.2005.05.013.CrossRefPubMedGoogle Scholar
  7. Gomes AV, Liang J, Potter JD. Mutations in human cardiac troponin I that are associated with restrictive cardiomyopathy affect basal ATPase activity and the calcium sensitivity of force development. J Biol Chem. 2005b;280:30909–15. doi: 10.1074/jbc.M500287200.CrossRefPubMedGoogle Scholar
  8. Greaser ML, Gergely J. Reconstitution of troponin activity from three protein components. J Biol Chem. 1971;246:4226–33.PubMedGoogle Scholar
  9. Hwang PM, Cai F, Pineda-Sanabria SE, Corson DC, Sykes BD. The cardiac-specific N-terminal region of troponin I positions the regulatory domain of troponin C. Proc Natl Acad Sci USA. 2014;111:14412–7. doi: 10.1073/pnas.1410775111.CrossRefPubMedPubMedCentralGoogle Scholar
  10. Ishii Y, Lehrer SS. Two-site attachment of troponin to pyrene-labeled tropomyosin. J Biol Chem. 1991;266:6894–903.PubMedGoogle Scholar
  11. Li MX, Hwang PM. Structure and function of cardiac troponin C (TNNC1): implications for heart failure, cardiomyopathies, and troponin modulating drugs. Gene. 2015;571:153–66. doi: 10.1016/j.gene.2015.07.074.CrossRefPubMedPubMedCentralGoogle Scholar
  12. Li MX, Spyracopoulos L, Sykes BD. Binding of cardiac troponin-I147-163 induces a structural opening in human cardiac troponin-C. Biochemistry. 1999;38:8289–98. doi: 10.1021/bi9901679.CrossRefPubMedGoogle Scholar
  13. Lu QW, Wu XY, Morimoto S. Inherited cardiomyopathies caused by troponin mutations. J Geriatr Cardiol. 2013;10:91–101. doi: 10.3969/j.issn.1671-5411.2013.01.014.PubMedPubMedCentralGoogle Scholar
  14. Morimoto S, Lu QW, Harada K, Takahashi-Yanaga F, Minakami R, Ohta M, et al. Ca(2+)-desensitizing effect of a deletion mutation Delta K210 in cardiac troponin T that causes familial dilated cardiomyopathy. Proc Natl Acad Sci USA. 2002;99:913–8. doi: 10.1073/pnas.022628899.CrossRefPubMedPubMedCentralGoogle Scholar
  15. Murakami K, Stewart M, Nozawa K, Tomii K, Kudou N, Igarashi N, et al. Structural basis for tropomyosin overlap in thin (actin) filaments and the generation of a molecular swivel by troponin-T. Proc Natl Acad Sci USA. 2008;105:7200–5. doi: 10.1073/pnas.0801950105.CrossRefPubMedPubMedCentralGoogle Scholar
  16. Parvatiyar MS, Pinto JR, Dweck D, Potter JD. Cardiac troponin mutations and restrictive cardiomyopathy. J Biomed Biotechnol. 2010;2010:350706. doi: 10.1155/2010/350706.CrossRefPubMedPubMedCentralGoogle Scholar
  17. Pinto JR, Yang SW, Hitz MP, Parvatiyar MS, Jones MA, Liang J, et al. Fetal cardiac troponin isoforms rescue the increased Ca2+ sensitivity produced by a novel double deletion in cardiac troponin T linked to restrictive cardiomyopathy: a clinical, genetic, and functional approach. J Biol Chem. 2011;286:20901–12. doi: 10.1074/jbc.M111.234336.CrossRefPubMedPubMedCentralGoogle Scholar
  18. Sheng JJ, Jin JP. TNNI1, TNNI2 and TNNI3: evolution, regulation, and protein structure-function relationships. Gene. 2016;576:385–94. doi: 10.1016/j.gene.2015.10.052.CrossRefPubMedGoogle Scholar
  19. Sia SK, Li MX, Spyracopoulos L, Gagne SM, Liu W, Putkey JA, et al. Structure of cardiac muscle troponin C unexpectedly reveals a closed regulatory domain. J Biol Chem. 1997;272:18216–21.CrossRefPubMedGoogle Scholar
  20. Solaro RJ, Henze M, Kobayashi T. Integration of troponin I phosphorylation with cardiac regulatory networks. Circ Res. 2013;112:355–66. doi: 10.1161/CIRCRESAHA.112.268672.CrossRefPubMedPubMedCentralGoogle Scholar
  21. Sommese RF, Nag S, Sutton S, Miller SM, Spudich JA, Ruppel KM. Effects of troponin T cardiomyopathy mutations on the calcium sensitivity of the regulated thin filament and the actomyosin cross-bridge kinetics of human beta-cardiac myosin. PloS one. 2013;8:e83403. doi: 10.1371/journal.pone.0083403.CrossRefPubMedPubMedCentralGoogle Scholar
  22. Sumandea MP, Pyle WG, Kobayashi T, de Tombe PP, Solaro RJ. Identification of a functionally critical protein kinase C phosphorylation residue of cardiac troponin T. J Biol Chem. 2003;278:35135–44. doi: 10.1074/jbc.M306325200.CrossRefPubMedGoogle Scholar
  23. Takeda S, Yamashita A, Maeda K, Maeda Y. Structure of the core domain of human cardiac troponin in the Ca(2+)-saturated form. Nature. 2003;424:35–41. doi: 10.1038/nature01780.CrossRefPubMedGoogle Scholar
  24. Tripet B, Van Eyk JE, Hodges RS. Mapping of a second actin-tropomyosin and a second troponin C binding site within the C terminus of troponin I, and their importance in the Ca2+-dependent regulation of muscle contraction. J Mol Biol. 1997;271:728–50. doi: 10.1006/jmbi.1997.1200.CrossRefPubMedGoogle Scholar
  25. Wei B, Jin JP. TNNT1, TNNT2, and TNNT3: isoform genes, regulation, and structure-function relationships. Gene. 2016;582:1–13. doi: 10.1016/j.gene.2016.01.006.CrossRefPubMedPubMedCentralGoogle Scholar
  26. Wijnker PJ, Murphy AM, Stienen GJ, van der Velden J. Troponin I phosphorylation in human myocardium in health and disease. Neth Heart J. 2014;22:463–9. doi: 10.1007/s12471-014-0590-4.CrossRefPubMedPubMedCentralGoogle Scholar
  27. Zhang R, Zhao J, Mandveno A, Potter JD. Cardiac troponin I phosphorylation increases the rate of cardiac muscle relaxation. Circ Res. 1995;76:1028–35.CrossRefPubMedGoogle Scholar
  28. Zhang P, Kirk JA, Ji W, dos Remedios CG, Kass DA, Van Eyk JE, et al. Multiple reaction monitoring to identify site-specific troponin I phosphorylated residues in the failing human heart. Circulation. 2012;126:1828–37. doi: 10.1161/CIRCULATIONAHA.112.096388.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Department of BiochemistryUniversity of AlbertaEdmontonCanada
  2. 2.Department of MedicineUniversity of AlbertaEdmontonCanada